CL2007003666A1 - Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras. - Google Patents

Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.

Info

Publication number: CL2007003666A1
Authority: CL; Chile
Prior art keywords: compounds; psoriasis; arthritis; treatment; multiple sclerosis
Prior art date: 2006-12-22

Application number

CL200703666A

Other languages

English (en)

Inventor

Cesar Castro Palomino La Julio

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-22

Filing date

2007-12-17

Publication date

2008-07-04

2007-04-23 Priority claimed from ES200701086A external-priority patent/ES2327372B1/es

2007-12-17 Application filed by Almirall Lab filed Critical Almirall Lab

2008-07-04 Publication of CL2007003666A1 publication Critical patent/CL2007003666A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 2
201000004681 Psoriasis Diseases 0.000 title 1
206010003246 arthritis Diseases 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1
229960003512 nicotinic acid Drugs 0.000 title 1
235000001968 nicotinic acid Nutrition 0.000 title 1
239000011664 nicotinic acid Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

CL200703666A 2006-12-22 2007-12-17 Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras. CL2007003666A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200603250A ES2319596B1 (es)	2006-12-22	2006-12-22	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES200701086A ES2327372B1 (es)	2007-04-23	2007-04-23	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.

Publications (1)

Publication Number	Publication Date
CL2007003666A1 true CL2007003666A1 (es)	2008-07-04

Family

ID=39319647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703666A CL2007003666A1 (es)	2006-12-22	2007-12-17	Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.

Country Status (31)

Country	Link
US (2)	US8258308B2 (es)
EP (1)	EP2121614B1 (es)
JP (1)	JP5318776B2 (es)
KR (1)	KR101435233B1 (es)
CN (1)	CN101589025B (es)
AR (1)	AR064444A1 (es)
AU (1)	AU2007338321B2 (es)
BR (1)	BRPI0717697B1 (es)
CA (1)	CA2674512C (es)
CL (1)	CL2007003666A1 (es)
CY (1)	CY1113687T1 (es)
DK (1)	DK2121614T3 (es)
EC (1)	ECSP099395A (es)
ES (2)	ES2319596B1 (es)
HR (1)	HRP20120697T1 (es)
IL (1)	IL199188A (es)
ME (1)	ME01475B (es)
MX (1)	MX2009006408A (es)
MY (1)	MY153393A (es)
NO (1)	NO341991B1 (es)
NZ (1)	NZ577017A (es)
PE (1)	PE20081846A1 (es)
PL (1)	PL2121614T3 (es)
PT (1)	PT2121614E (es)
RS (1)	RS52514B (es)
RU (1)	RU2469024C2 (es)
SI (1)	SI2121614T1 (es)
TW (1)	TWI405572B (es)
UY (1)	UY30794A1 (es)
WO (1)	WO2008077639A1 (es)
ZA (1)	ZA200903335B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polimorfos
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2327372B1 (es) *	2007-04-23	2010-08-24	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (en) *	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110093841A (ko) *	2008-11-07	2011-08-18	4에스체 악티엔게젤샤프트	자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법
EP2196465A1 (en)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en)	2009-02-27	2010-09-08	Almirall, S.A.	New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228367A1 (en)	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
TWI530286B (zh) *	2009-05-04	2016-04-21	帕納特斯製藥格斯有限公司	作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) *	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
EP2338888A1 (en)	2009-12-24	2011-06-29	Almirall, S.A.	Imidazopyridine derivatives as JAK inhibitors
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2360158A1 (en)	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazole derivatives as jak inhibitors
EP2380890A1 (en)	2010-04-23	2011-10-26	Almirall, S.A.	New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en)	2010-05-06	2014-04-01	Rhizen Pharmaceuticals Sa	Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444088A1 (en)	2010-10-22	2012-04-25	Almirall, S.A.	Amino derivatives for the treatment of proliferative skin disorders
EP2444086A1 (en)	2010-10-22	2012-04-25	Almirall, S.A.	Combinations comprising DHODH inhibitors and COX inhibitors
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
EP2455080A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of crohn's disease
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2672963A4 (en)	2011-02-08	2015-06-24	Childrens Medical Center	METHOD FOR THE TREATMENT OF MELANOMA
US10016402B2 (en) *	2011-02-08	2018-07-10	Children's Medical Center Corporation	Methods for treatment of melanoma
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2518070A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	New CRTH2 Antagonists
EP2527344A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548876A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists
EP2548863A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists.
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en)	2011-11-21	2013-05-22	Almirall, S.A.	2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2014060431A1 (en)	2012-10-16	2014-04-24	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
TWI638814B (zh)	2012-10-31	2018-10-21	富山化學工業股份有限公司	新穎之胺衍生物或其鹽
TW201446767A (zh)	2013-02-15	2014-12-16	Almirall Sa	作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
WO2015077535A2 (en)	2013-11-22	2015-05-28	Genzyme Corporation	Novel methods for treating neurodegenerative diseases
RU2016144238A (ru)	2014-04-11	2018-05-11	Паноптес Фарма Гмбх	Противовоспалительные средства в качестве вирусостатических соединений
JP6629840B2 (ja) *	2014-05-08	2020-01-15	パノプテス・ファーマ・ゲーエムベーハー	眼の疾患および障害を処置するための化合物
WO2016200778A1 (en) *	2015-06-08	2016-12-15	Children's Medical Center Corporation	Methods for treatment of melanoma
WO2016202800A1 (en)	2015-06-16	2016-12-22	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2018136010A1 (en)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Combination therapy
WO2018136009A1 (en)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Combination therapy
US11311548B2 (en)	2017-03-02	2022-04-26	Aslan Pharmaceuticals Pte. Ltd.	Cancer therapy
CN108530310B (zh) *	2017-03-02	2025-01-28	中国科学院上海药物研究所	2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
TW201834649A (zh)	2017-03-02	2018-10-01	新加坡商亞獅康私人有限公司	癌症療法
JP6978251B2 (ja) *	2017-03-03	2021-12-08	アスランファーマシューティカルズピーティーイーリミテッド	がん治療
WO2018222135A1 (en)	2017-06-02	2018-12-06	Aslan Pharmaceuticals Pte Ltd	Cancer therapy
WO2018222134A1 (en)	2017-06-02	2018-12-06	Aslan Pharmaceuticals Pte Ltd	Cancer therapy
AU2019232153B2 (en)	2018-03-09	2023-07-13	Panoptes Pharma Ges.M.B.H.	Ophthalmic formulation
EP3858361B1 (en)	2018-09-28	2025-10-08	FUJIFILM Corporation	Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine
WO2020130077A1 (ja)	2018-12-21	2020-06-25	国立大学法人北海道大学	多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法
EP3750892A1 (en)	2019-06-14	2020-12-16	Yerevan State University	Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
EP4052760B1 (en) *	2019-10-31	2024-03-13	FUJIFILM Corporation	Pyrazine derivative or salt thereof, and use of same
EP4190402B1 (en) *	2020-07-30	2025-08-27	FUJIFILM Corporation	Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof
US20230390276A1 (en) *	2020-10-15	2023-12-07	Aslan Pharmaceuticals Pte. Ltd.	Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CN116940359A (zh) *	2020-10-15	2023-10-24	亚狮康私人有限公司	用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病
WO2023278778A1 (en) *	2021-06-30	2023-01-05	Ohio State Innovation Foundation	Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
WO2023147161A2 (en) *	2022-01-31	2023-08-03	New Frontier Bio, Inc.	Nicotinate and nicotinamide riboside-based compounds and derivatives thereof
WO2023149841A1 (en) *	2022-02-03	2023-08-10	Aslan Pharmaceuticals Pte Ltd	Dhodh inhibitor polymorph
JP2025513444A (ja) *	2022-04-21	2025-04-24	アスランファーマシューティカルズピーティーイーリミテッド	自己免疫性皮膚疾患の治療
WO2025215126A1 (en)	2024-04-12	2025-10-16	Immunic Ag	Synthesis of vidofludimus and its calcium salt
CN119979562B (zh) *	2025-02-28	2026-04-17	南京农业大学	水稻gif4基因在调控籽粒灌浆和粒重中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US529490A (en) *		1894-11-20		hegg-em
EP0008532B1 (en) *	1978-08-22	1983-07-20	Sumitomo Chemical Company, Limited	Synthesis of amines
JPH05331163A (ja) *	1991-03-26	1993-12-14	Kumiai Chem Ind Co Ltd	ピリジン誘導体及び除草剤
DE69429078T2 (de) *	1993-10-01	2002-07-11	Novartis Ag, Basel	Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
PL182198B1 (en)	1995-06-21	2001-11-30	Asta Medica Ag	Pharmaceutic powder holding container with integrated measuring device and powdered
DE19547648A1 (de)	1995-12-20	1997-06-26	Hoechst Ag	Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de)	1996-03-20	1997-09-25	Hoechst Ag	Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en)	1998-02-27	1998-04-22	Univ Cardiff	Chemical compounds
IL146971A0 (en) *	1999-06-10	2002-08-14	Warner Lambert Co	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
DK1381356T3 (da)	2001-04-05	2008-09-22	Aventis Pharma Inc	Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
PE20030120A1 (es)	2001-06-19	2003-02-12	Merck & Co Inc	Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) *	2001-07-10	2005-07-25	4Sc Ag	Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de)	2002-01-24	2003-07-31	Sofotec Gmbh & Co Kg	Patrone für einen Pulverinhalator
US7258118B2 (en)	2002-01-24	2007-08-21	Sofotec Gmbh & Co, Kg	Pharmaceutical powder cartridge, and inhaler equipped with same
AR042206A1 (es)	2002-11-26	2005-06-15	Novartis Ag	Acidos fenilaceticos y derivados
WO2004056746A1 (en)	2002-12-23	2004-07-08	4Sc Ag	Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) *	2002-12-23	2004-07-08	4Sc Ag	Dhodh-inhibitors and method for their identification
SE0400234D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New compounds, methods for their preparation and use thereof
AU2005257862A1 (en)	2004-05-21	2006-01-05	The Uab Research Foundation	Compositions and methods relating to pyrimidine synthesis inhibitors
WO2006022442A1 (ja) *	2004-08-24	2006-03-02	Santen Pharmaceutical Co., Ltd.	ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
SG142305A1 (en)	2004-10-19	2008-05-28	Aventis Pharma Inc	Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
ES2444866T3 (es) *	2004-10-20	2014-02-27	Merck Serono Sa	Derivados de 3-arilamino piridina
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ATE508108T1 (de)	2007-02-06	2011-05-15	Chelsea Therapeutics Inc	Neue verbindungen, verfahren zu deren herstellung und deren verwendung
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en)	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en)	2009-01-21	2010-07-28	Almirall, S.A.	Combinations comprising methotrexate and DHODH inhibitors
EP2230232A1 (en)	2009-03-13	2010-09-22	Almirall, S.A.	Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en)	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en)	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

2006
- 2006-12-22 ES ES200603250A patent/ES2319596B1/es not_active Withdrawn - After Issue
2007
- 2007-12-13 UY UY30794A patent/UY30794A1/es active IP Right Grant
- 2007-12-17 CL CL200703666A patent/CL2007003666A1/es unknown
- 2007-12-17 TW TW096148215A patent/TWI405572B/zh not_active IP Right Cessation
- 2007-12-19 AR ARP070105721A patent/AR064444A1/es active IP Right Grant
- 2007-12-21 NZ NZ577017A patent/NZ577017A/en unknown
- 2007-12-21 ME MEP-2012-104A patent/ME01475B/me unknown
- 2007-12-21 RU RU2009127847/04A patent/RU2469024C2/ru active
- 2007-12-21 AU AU2007338321A patent/AU2007338321B2/en not_active Ceased
- 2007-12-21 JP JP2009541921A patent/JP5318776B2/ja not_active Expired - Fee Related
- 2007-12-21 CN CN200780047756XA patent/CN101589025B/zh active Active
- 2007-12-21 ES ES07866261T patent/ES2389785T3/es active Active
- 2007-12-21 KR KR1020097012714A patent/KR101435233B1/ko not_active Expired - Fee Related
- 2007-12-21 SI SI200731012T patent/SI2121614T1/sl unknown
- 2007-12-21 BR BRPI0717697-0A patent/BRPI0717697B1/pt active IP Right Grant
- 2007-12-21 RS RS20120388A patent/RS52514B/sr unknown
- 2007-12-21 CA CA2674512A patent/CA2674512C/en active Active
- 2007-12-21 PT PT07866261T patent/PT2121614E/pt unknown
- 2007-12-21 PL PL07866261T patent/PL2121614T3/pl unknown
- 2007-12-21 HR HRP20120697TT patent/HRP20120697T1/hr unknown
- 2007-12-21 MY MYPI20092607A patent/MY153393A/en unknown
- 2007-12-21 EP EP07866261A patent/EP2121614B1/en active Active
- 2007-12-21 DK DK07866261.6T patent/DK2121614T3/da active
- 2007-12-21 MX MX2009006408A patent/MX2009006408A/es active IP Right Grant
- 2007-12-21 US US12/520,237 patent/US8258308B2/en active Active
- 2007-12-21 WO PCT/EP2007/011401 patent/WO2008077639A1/en not_active Ceased
2008
- 2008-01-02 PE PE2008000062A patent/PE20081846A1/es active IP Right Grant
2009
- 2009-05-14 ZA ZA200903333A patent/ZA200903335B/xx unknown
- 2009-06-04 IL IL199188A patent/IL199188A/en active IP Right Grant
- 2009-06-09 EC EC2009009395A patent/ECSP099395A/es unknown
- 2009-06-22 NO NO20092380A patent/NO341991B1/no unknown
2012
- 2012-08-06 US US13/567,437 patent/US8691852B2/en not_active Expired - Fee Related
- 2012-09-04 CY CY20121100791T patent/CY1113687T1/el unknown

Also Published As

Publication number	Publication date
ES2389785T3 (es)	2012-10-31
PE20081846A1 (es)	2008-12-27
AU2007338321B2 (en)	2012-01-19
SI2121614T1 (sl)	2012-10-30
US20100074898A1 (en)	2010-03-25
RS52514B (sr)	2013-04-30
RU2009127847A (ru)	2011-01-27
HK1133014A1 (en)	2010-03-12
US8691852B2 (en)	2014-04-08
US8258308B2 (en)	2012-09-04
CN101589025A (zh)	2009-11-25
PL2121614T3 (pl)	2012-11-30
JP5318776B2 (ja)	2013-10-16
NZ577017A (en)	2011-12-22
NO20092380L (no)	2009-07-14
UY30794A1 (es)	2008-05-31
JP2010513362A (ja)	2010-04-30
PT2121614E (pt)	2012-08-31
BRPI0717697A2 (pt)	2016-03-22
ES2319596B1 (es)	2010-02-08
RU2469024C2 (ru)	2012-12-10
MX2009006408A (es)	2009-06-23
KR101435233B1 (ko)	2014-08-28
DK2121614T3 (da)	2012-09-17
WO2008077639A1 (en)	2008-07-03
CN101589025B (zh)	2012-05-30
IL199188A (en)	2014-06-30
TW200833332A (en)	2008-08-16
ME01475B (me)	2014-04-20
BRPI0717697B1 (pt)	2022-05-03
TWI405572B (zh)	2013-08-21
CA2674512A1 (en)	2008-07-03
ES2319596A1 (es)	2009-05-08
HRP20120697T1 (hr)	2012-09-30
ZA200903335B (en)	2010-06-30
MY153393A (en)	2015-02-13
KR20090090352A (ko)	2009-08-25
EP2121614A1 (en)	2009-11-25
EP2121614B1 (en)	2012-06-20
AU2007338321A1 (en)	2008-07-03
CA2674512C (en)	2015-09-08
NO341991B1 (no)	2018-03-12
ECSP099395A (es)	2009-07-31
US20120294854A1 (en)	2012-11-22
AR064444A1 (es)	2009-04-01
CY1113687T1 (el)	2016-06-22

Publication	Publication Date	Title
CL2007003423A1 (es)	2008-07-18	Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007002330A1 (es)	2008-02-15	Compuestos derivados de oxo aza antraceno; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el rechazo de trasplante, artritis reumatoide, artritis psoriatica, esclerosis multiple, asma, entre otras.
CL2007003774A1 (es)	2008-04-18	Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2009000650A1 (es)	2010-03-26	Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2012001627A1 (es)	2012-10-05	Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007002424A1 (es)	2008-02-08	Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007003352A1 (es)	2008-07-04	Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
CL2008000691A1 (es)	2008-09-12	Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007002974A1 (es)	2008-05-23	Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2007002479A1 (es)	2008-02-29	Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
CL2008003119A1 (es)	2010-01-04	Compuestos derivados de piridina o piridazina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de un estado inflamatorio y/o autoinmune tal como artritis reumatoide.
CL2008000946A1 (es)	2008-10-10	Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
CL2008002315A1 (es)	2009-11-13	Compuestos derivados de acido piridin, pirimidin y quinolin aminonbenzoico; composicion y combinacion farmaceuticas; y uso para el tratamiento de una enfermedad susceptible de aliviarse mediante la inhibicion de deshidroorotato deshidrogenasa tales como artritis reumatoide, espondilitis anquilosante, esclerosis multiple, psoriasis, entre otras.
CL2007003627A1 (es)	2008-07-25	Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias
CL2008000224A1 (es)	2008-05-23	Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
CL2008000330A1 (es)	2008-08-08	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.
CL2007002121A1 (es)	2008-02-22	Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007001023A1 (es)	2008-03-14	Compuestos derivados de cromen-2-ona; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica, utiles para el tratamiento o prevencion de trastornos o enfermedades mediadas por los linfocitos-t, tal como artritis reumatoide y diabe
CL2007003758A1 (es)	2008-07-04	Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
CL2008002295A1 (es)	2009-03-27	Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.